Start here if you're new
what it is
Certara sells software and services that help drug companies test medicines on computers before spending money on real trials.
how it gets paid
Last year Certara made $419M in revenue. biosimulation software was the main engine at $151M, or 36% of sales.
why it's growing
Revenue grew 8.7% last year. Trailing annual revenue was $419M, up 8.7% vs. prior year, while the latest reported quarter showed revenue of $315M, up 201% vs. prior year.
what just happened
Latest earnings were small, but the surprise was huge: EPS came in at $0.09 versus a $0.02 estimate.
At a glance
B+ balance sheet — decent shape, but not bulletproof
30/100 earnings predictability — expect surprises
16.0x trailing p/e — the market's not buying it — or you found a deal
6.0% return on capital — nothing to write home about
xvary composite: 41/100 — below average
What they do
Certara sells software and services that help drug companies test medicines on computers before spending money on real trials.
Drug development is slow, expensive, and full of failure. Certara sells time. Its annual revenue is $419M, and customers use its software and services to run virtual trials before real ones, which means fewer costly mistakes. Once your data, workflows, and regulatory submissions run through one system, switching gets painful.
How they make money
$419M
annual revenue · their business grew +8.7% last year
biosimulation software
$151M
regulatory software
$71M
scientific services
$126M
clinical pharmacology services
$50M
data and platform tools
$21M
The products that matter
drug development modeling platform
biosimulation software
$0.4B revenue · 39% market share
it holds a 39% share in its niche and supports the full $0.4B revenue base shown in this snapshot. the data here does not break out software versus services, which means you are underwriting the whole platform, not a neat segment mix.
core engine
Key numbers
$419M
annual revenue
This is the current scale. Your bet is that management can turn a $419M niche drug-software business into something much larger.
5.0%
operating margin
Operating margin → money left after running the business → so what: Certara has very little room for mistakes.
16.0x
trailing p/e
P/E → price divided by past earnings → so what: you are not paying a crazy multiple, but you are paying for a turnaround.
$290M
long-term debt
Debt → money the company owes → so what: leverage matters more when returns on capital are only 6.0%.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 4 — safer than 20% of stocks
- price stability 10 / 100
- long-term debt $290M (21% of capital)
- net profit margin 19.4% — keeps 19 cents of every dollar in revenue
- return on equity 7% — $0.07 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in CERT 3 years ago → it's now worth $3,340.
The index would have given you $14,540.
source: institutional data · total return
What just happened
beat estimates
Latest earnings were small, but the surprise was huge: EPS came in at $0.09 versus a $0.02 estimate.
Trailing annual revenue was $419M, up 8.7% vs. prior year, while the latest reported quarter showed revenue of $315M, up 201% vs. prior year. The business is improving, but the reported quarter looks distorted next to the full-year base.
$315M
revenue
$0.09
eps
n/a
n/a
the number that mattered
The 350% EPS surprise matters because it shows expectations were low and Certara cleared them easily.
-
certara appointed a new ceo.the struggling provider of software and technology-enabled services for drug developers replaced william feehery with jon resnick on january 1st.
-
mr.
-
feehery had led the company since 2019.
-
mr.resnick was president of iqvia’s u.s. and canadian operations and has spent more than two decades in the healthcare data, analytics, and life sciences space. he will likely bring added understanding of pharmaceutical r&d workflows and commercialization strategies. this should align with biosimulation software which has gained regulatory support and enables researchers to model drug safety and efficacy during development.
-
nonetheless, the stock price slid roughly 20% over the last three months.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is failing to turn a 39% biosimulation software lead into faster growth under a new ceo.
med
execution under the new ceo
jon resnick took over on january 1. a leadership reset can sharpen the story, or reveal that the old growth problem was structural.
earnings predictability is only 30/100, so misses are likely to hit the stock harder than they would at a steadier software company.
med
share erosion in a narrow niche
39% market share is the moat. if that slips, the whole premium-niche argument gets smaller fast.
on a $0.4B revenue base, slower adoption or pricing pressure has nowhere to hide.
med
debt matters more when scale is limited
$290M of long-term debt equals 21% of capital. that is manageable, but not invisible, for a company worth about $1B.
if growth cools, leverage becomes a valuation issue before it becomes a solvency issue.
med
institutional support keeps fading
institutions have been net sellers for two straight quarters, including 86 buyers versus 91 sellers in 4Q2025.
small caps without sponsorship can stay cheap far longer than fundamentals alone would suggest.
put it together and you have a $1B stock with real niche leadership, modest growth, and very little room for execution drift.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
revenue growth versus the 8.7% full-year pace
if quarterly growth cannot stay above last year's 8.7%, the cheap multiple is probably telling the truth.
calendar
the first two quarters under jon resnick
new ceo narratives are easy. two reporting cycles are where you find out whether the reset is real.
trend
whether institutional selling stops
two straight quarters of net selling is a trend. a reversal would matter more here than at a megacap.
risk
margin durability at 17.3%
profitability is one of the few clean positives in this snapshot. if it slips while growth stays modest, the story gets thinner fast.
Analyst rankings
short-term outlook
below average
momentum score 4 — in human-speak, analysts think this could lag most stocks over the next year.
risk profile
below average
stability score 4 — safer than only 20% of stocks. translation: expect bigger swings, not a smoother ride.
chart momentum
average
technical score 3 — the chart is not flashing a strong signal either way.
earnings predictability
30 / 100
only 30/100 — these results are harder to model than you would want from a software company.
source: institutional data
Institutional activity
institutions have been net selling for 2 consecutive quarters — 86 buyers vs. 91 sellers in 4q2025. total institutional holdings: 0.1B shares. net selling for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$4
$14
$7
current price
$9
target midpoint · +28% from current · 3-5yr high: $25 (+255% · 37% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive